CL2019000729A1 - Proteínas de unión recombinantes y sus usos. - Google Patents

Proteínas de unión recombinantes y sus usos.

Info

Publication number
CL2019000729A1
CL2019000729A1 CL2019000729A CL2019000729A CL2019000729A1 CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1 CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1
Authority
CL
Chile
Prior art keywords
union
recombinating
associdus
proteins
binding proteins
Prior art date
Application number
CL2019000729A
Other languages
English (en)
Spanish (es)
Inventor
Clara Metz
Ulrike Fiedler
Ignacio Dolado
Heike Maria Strobel
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of CL2019000729A1 publication Critical patent/CL2019000729A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2019000729A 2016-09-22 2019-03-21 Proteínas de unión recombinantes y sus usos. CL2019000729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16190221 2016-09-22

Publications (1)

Publication Number Publication Date
CL2019000729A1 true CL2019000729A1 (es) 2019-06-14

Family

ID=57046984

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000729A CL2019000729A1 (es) 2016-09-22 2019-03-21 Proteínas de unión recombinantes y sus usos.

Country Status (20)

Country Link
US (2) US10717772B2 (enExample)
EP (1) EP3515933B9 (enExample)
JP (1) JP6976335B2 (enExample)
KR (1) KR102270315B1 (enExample)
CN (1) CN109790206A (enExample)
AR (1) AR109680A1 (enExample)
AU (1) AU2017331329B2 (enExample)
BR (1) BR112019005587A2 (enExample)
CA (1) CA3036301C (enExample)
CL (1) CL2019000729A1 (enExample)
CO (1) CO2019002609A2 (enExample)
ES (1) ES2953516T3 (enExample)
IL (1) IL265489B (enExample)
MX (1) MX377424B (enExample)
MY (1) MY196882A (enExample)
NZ (1) NZ751689A (enExample)
PH (1) PH12019500596B1 (enExample)
SA (1) SA519401369B1 (enExample)
WO (1) WO2018054971A1 (enExample)
ZA (1) ZA201901592B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119080A1 (es) * 2019-06-04 2021-11-24 Molecular Partners Ag Proteínas multiespecíficas
SG11202112925PA (en) * 2019-06-04 2021-12-30 Molecular Partners Ag Recombinant fap binding proteins and their use
JP7742309B2 (ja) 2019-06-04 2025-09-19 モレキュラー パートナーズ アクチェンゲゼルシャフト 改善された安定性を有する設計されたアンキリン反復ドメイン
US20220298212A1 (en) * 2019-06-04 2022-09-22 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
CN114929730A (zh) 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
WO2021224686A1 (en) 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
WO2021229076A1 (en) * 2020-05-14 2021-11-18 Molecular Partners Ag Recombinant cd40 binding proteins and their use
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
KR20230155464A (ko) 2021-03-09 2023-11-10 몰리큘라 파트너스 아게 신규한 DARPin-기반 다중특이성 T-세포 인게이저
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のDARPinに基づくCD33エンゲージャ
AU2022232216A1 (en) 2021-03-09 2023-10-05 Molecular Partners Ag Protease cleavable prodrugs
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024251742A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd2 binding proteins and their use
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
WO2003018611A2 (en) * 2001-08-24 2003-03-06 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
KR20140039203A (ko) 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2906591A1 (en) * 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
PH12017501792B1 (en) * 2015-04-02 2022-07-20 Molecular Partners Ag Recombinant binding proteins and their use

Also Published As

Publication number Publication date
BR112019005587A2 (pt) 2019-06-11
ZA201901592B (en) 2021-04-28
MX2019003298A (es) 2019-09-26
WO2018054971A1 (en) 2018-03-29
MY196882A (en) 2023-05-08
CA3036301A1 (en) 2018-03-29
AU2017331329B2 (en) 2020-10-29
CN109790206A (zh) 2019-05-21
PH12019500596B1 (en) 2024-02-21
US20180155402A1 (en) 2018-06-07
EP3515933C0 (en) 2023-06-07
NZ751689A (en) 2021-07-30
KR102270315B1 (ko) 2021-06-29
AR109680A1 (es) 2019-01-09
EP3515933A1 (en) 2019-07-31
PH12019500596A1 (en) 2019-07-29
CA3036301C (en) 2021-04-20
US10717772B2 (en) 2020-07-21
US20210130420A1 (en) 2021-05-06
MX377424B (es) 2025-03-10
EP3515933B1 (en) 2023-06-07
RU2019111628A (ru) 2020-10-19
RU2019111628A3 (enExample) 2020-10-30
EP3515933B9 (en) 2023-08-16
JP6976335B2 (ja) 2021-12-08
IL265489A (en) 2019-05-30
AU2017331329A1 (en) 2019-04-04
ES2953516T3 (es) 2023-11-14
JP2019531093A (ja) 2019-10-31
CO2019002609A2 (es) 2019-05-31
SA519401369B1 (ar) 2022-12-22
IL265489B (en) 2021-07-29
KR20190050802A (ko) 2019-05-13

Similar Documents

Publication Publication Date Title
CL2019000729A1 (es) Proteínas de unión recombinantes y sus usos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
CL2019000628A1 (es) Anticuerpos anti-pd-1 y sus usos.
MX2018003491A (es) Represores de htt y usos de estos.
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
MX2019008359A (es) Cadena j modificada.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
PE20170256A1 (es) Proteinas de union y sus metodos de uso
MX391249B (es) Anticuerpos anti-muc16 y sus usos.
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
MX2017010117A (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
UY35964A (es) Anticuerpos humanos para pd?1
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
MX2019004690A (es) Constructos de anticuerpos.
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
DK3345613T3 (da) Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel